CN100493558C - Oral liquid for apoplexy - Google Patents
Oral liquid for apoplexy Download PDFInfo
- Publication number
- CN100493558C CN100493558C CNB2006100349592A CN200610034959A CN100493558C CN 100493558 C CN100493558 C CN 100493558C CN B2006100349592 A CNB2006100349592 A CN B2006100349592A CN 200610034959 A CN200610034959 A CN 200610034959A CN 100493558 C CN100493558 C CN 100493558C
- Authority
- CN
- China
- Prior art keywords
- gram
- apoplexy
- oral liquid
- treatment
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of oral liquid for treating ischemic apoplexy and its sequelae is prepared from 8 Chinese-medicinal materials including prepared rehmannia rot, dried yam, tuckahoe, Chuan-xiong rhizome, etc through decocting and concentrating.
Description
Technical field
The present invention relates to the field of Chinese medicines, particularly a kind of apoplexy oral liquid that is used for the treatment of the cerebral infarction disease.
Background technology
Cerebral infarction claims cerebral infarction again, is meant because brain blood circulation obstacle, the ischemic necrosis of the limitation cerebral tissue that ischemia, anoxia cause or the clinical syndrome that cerebral malacia causes.Apoplexy, the definition that proposes according to the scorching academician of Wang Yong: on the basis of QI and blood interior-deficiency, meet the overstrain internal injury, be worried angry, have a liking for inducements such as food savoury, tobacco and wine, and then causing the internal organs imbalance of YIN and YANG, QI and blood is contrary disorderly, the criminal's of flinging brain, forms outside resistance of brain BI-syndrome involved the blood vessels or the blood oozing from the body openings or subcuta neous tissue arteries and veins.Clinical five big primary symptoms: lose consciousness servant, hemiplegia, crooked mouth and tongue, dysphasia or in silence suddenly, hemianesthesia.
Apoplexy has become one of the world today's last three big causes of death, and very high at the sickness rate of China's apoplexy, wherein cerebral infarction accounts for 70-85%, and sickness rate has the trend that progressively rises in recent years.The present progress of making a breakthrough property not in treatment, the case fatality rate that causes thus, disability rate are still high, have brought white elephant for society and family.Therefore seek the effectively measure of control cerebral infarction, become the research topic that world medical circle is attracted attention.
To the treatment of apoplexy, it is generally acknowledged that the thrombolytic resurgent is the key of treatment with really effective brain protection rapidly, but the time window of thrombolytic resurgent is too short, has seriously limited the practicality of its treatment at present.The curative effect of treatment by Chinese herbs cerebral infarction is sure, and origin for a long time.Experimentation shows that some Chinese medicines have antagonism cerebral ischemia and many-sided cerebral protection.For example BUYANG HUANWU TANG is effective prescription of generally acknowledging, clinical and animal experiment confirms that the form and the function of brain tissue cell are had many-sided effect, is the general side of current cerebral infarction.But the various prescriptions that are based on thrombolytic resurgent theory and derive from; comprise BUYANG HUANWU TANG; its function mainly is to eliminate the phlegm based on blood circulation promoting and blood stasis dispelling, the meridian dredging; take stopgap measures and can not effect a permanent cure; not high at stroke in convalescent stage and sequela stage curative effect, so the development and utilization cerebral protective agent just becomes current research focus.
Summary of the invention
At the present deficiency of full brain-protection drugs research, the purpose of this invention is to provide a kind of apoplexy oral liquid, its be with the activating blood circulation method of tonifying Qi of the kidney as Therapeutic Principle's prescription, be applicable to the specimen medical treatment of suffering from acute stroke, convalescent care and sequela stage.
The object of the present invention is achieved like this: a kind of apoplexy oral liquid, it is characterized in that: prescription comprises following dosage component: Radix Rehmanniae Preparata 19-29 gram, Fructus Corni 10-14 gram, dried Rhizoma Dioscoreae 10-14 gram, Rhizoma Alismatis 7-11 gram, Cortex Moutan 7-11 gram, Poria 10-14 gram, Radix Astragali 90-140 gram, Rhizoma Chuanxiong 1-5 gram, concentrated decotion.
Component also comprises Semen Persicae 1-5 gram, Pheretima 1-5 gram.
Described dosage form also includes tablet, electuary or capsule.
Described apoplexy oral liquid is applied to the treatment of cerebral infarction acute phase of disease, convalescent period and sequela stage.
The present invention is this according to suffering from a deficiency of the kidney, and the resistance of the brain network stasis of blood reaches treating both the principal and secondary aspects of a disease for the target theory, can obviously improve patient's clinical disease, improves neurologic impairment, improves patient's activity of daily living, improves patient's clinical efficacy, is better than existing various prescription.
The specific embodiment
The present invention is a kind of apoplexy oral liquid, prescription comprises following dosage component: Radix Rehmanniae Preparata 19-29 gram, Fructus Corni 10-14 gram, dried Rhizoma Dioscoreae 10-14 gram, Rhizoma Alismatis 7-11 gram, Cortex Moutan 7-11 gram, Poria 10-14 gram, Radix Astragali 90-140 gram, Rhizoma Chuanxiong 1-5 gram, concentrated decotion gets final product.Also can comprise Semen Persicae 1-5 gram, Pheretima 1-5 gram in the component.According to actual needs, dosage form can be oral liquid, tablet, electuary or capsule etc.
We are the Therapeutic Principle to tonify Qi of the kidney, and are aided with promoting blood circulation to remove blood stasis simultaneously, and are evident in efficacy.Wherein, but Radix Rehmanniae Preparata nourishing the blood and yin, vital essence replenishing and marrow benifiting; But the Fructus Corni liver and kidney tonifying, the convergence astringent or styptic treatment for spontaneous sweating; But dried Rhizoma Dioscoreae supplementing QI and nourishing YIN, benefit Pi lung kidney; But the Rhizoma Alismatis promoting diuresis to eliminate damp pathogen, expel the heat-evil; But Cortex Moutan clearing away heat and cooling blood, promoting blood circulation to remove blood stasis; But Poria promoting diuresis to eliminate damp pathogen, strong Pi calm the nerves; But Radix Astragali tonifying Qi and lifting yang, benefit are defended consolidating superficial resistance, promoting pus discharge and tissue regeneration strengthening, diuretic detumescent; But Rhizoma Chuanxiong blood-activating and qi-promoting, wind-expelling pain-stopping; But Semen Persicae blood circulation promoting and blood stasis dispelling, loosening bowel to relieve constipation; But the Pheretima clearing heat for calming endogenous wind, relieving asthma, collateral dredging, diuresis, be good at the endogenous wind stopping relieving convulsion especially.Can see that the component in the prescription mainly is divided into two classes by its drug effect, a class is to be used for promoting blood circulation to remove blood stasis, and another kind of is to be used to tonify Qi of the kidney, and has further strengthened the curative effect of the kidney invigorating after component is arranged in pairs or groups mutually again.
Embodiment 1
Prescription comprises following dosage component: Radix Rehmanniae Preparata 19 grams, Fructus Corni 10 grams, dried Rhizoma Dioscoreae 10 grams, Rhizoma Alismatis 7 grams, Cortex Moutan 7 grams, Poria 10 grams, Radix Astragali 90 grams, Rhizoma Chuanxiong 1 gram, concentrated decotion.
Embodiment 2
Prescription comprises following dosage component: Radix Rehmanniae Preparata 24 grams, Fructus Corni 12 grams, dried Rhizoma Dioscoreae 12 grams, Rhizoma Alismatis 9 grams, Cortex Moutan 9 grams, Poria 12 grams, Radix Astragali 120 grams, Rhizoma Chuanxiong 3 grams, Semen Persicae 3 grams, Pheretima 3 grams, concentrated decotion.
Embodiment 3
Prescription comprises following dosage component: Radix Rehmanniae Preparata 29 restrains, Fructus Corni 14 restrains, dried Rhizoma Dioscoreae 14 restrains, Rhizoma Alismatis 11 restrains, Cortex Moutan 11 restrains, Poria 14 restrains, Radix Astragali 140 restrains, Rhizoma Chuanxiong 5 restrains, Semen Persicae 5 restrains, Pheretima 5 restrains concentrated decotions, and makes tablet by existing technology.
The curative effect comparision test
(1) Chinese patent medicines such as the present invention and existing HUATUO ZAIZAO WAN, BUYANG HUANWU TANG oral liquid carry out controlled clinical trial.
Controlled trial adopts the method for single at random blind positive drug contrast, and the case grouping is divided into treatment group and matched group with 1-64 case at random in the 1:1 ratio.
Treatment group: oral apoplexy oral liquid of the present invention, 3 times/day;
Matched group: oral HUATUO ZAIZAO WAN or BUYANG HUANWU TANG, 3 times/day;
Two groups all add each Chinese medicine preparation on the western medical treatment basis, 15 days was 1 course of treatment, observed for 1 course of treatment.
With reference to " the clinical research index principle of new Chinese medicine treatment apoplexy ", and abide by " clinical efficacy evaluation criteria " all data by statistical procedures, the result:
1. traditional Chinese medical science disease integration is 31 minutes before the treatment group treatment, treatment back integration is 16 minutes, can obviously reduce traditional Chinese medical science disease integration after the treatment reached more than 15 minutes, and matched group only descended below 10 minutes, this illustrates that apoplexy oral liquid of the present invention can improve the clinical disease of Ischemic Apoplexy Patients, and the effect that improves patient's traditional Chinese medical science disease integration is better than matched group.
2. neurological deficits score is 18 minutes before the treatment group treatment, be 9 minutes after the treatment, can obviously reduce neurological deficits score after the treatment reached more than 9 minutes, and matched group only descended below 5 minutes, illustrate that apoplexy oral liquid of the present invention can obviously reduce the neurologic impairment of Ischemic Apoplexy Patients, is better than matched group.
3. the activity of daily living scoring is 45 minutes before the treatment group treatment, be 71 minutes after the treatment, the activity of daily living scoring of treatment back obviously improves nearly more than 25 minutes, and matched group only improved 14 fens, illustrate that apoplexy oral liquid of the present invention can obviously improve patient's activity of daily living, be better than matched group, this is for being that following of terminal point incident has crucial meaning the disease medical science with the quality of life of improving the patient.
4. treatment group can obviously be improved clinical efficacy after treatment, recovery from illness+marked improvement rate reaches 55%, and matched group is fully recovered after treating+the marked improvement rate has only 27%, illustrates that apoplexy oral liquid of the present invention can obviously improve the clinical efficacy of Ischemic Apoplexy Patients, is better than matched group.
(2) Chinese patent medicines such as the present invention and existing HUATUO ZAIZAO WAN, BUYANG HUANWU TANG oral liquid carry out the animal controlled trial.
Laboratory animal: healthy Sprague-Dawley (SD) rat, the 20-22 monthly age, male, body weight 400-550 gram, regular grade, 120, be divided into treatment group and matched group, the treatment group is fed apoplexy oral liquid of the present invention, and matched group is fed HUATUO ZAIZAO WAN or BUYANG HUANWU TANG.Utilize the rat modeling to set up intraluminal middle cerebral artery occlusion in rats and block lasting cerebral ischemic model, and mark the result with reference to " modern pharmacology experimental methodology ":
1. after animal revives, observe function of nervous system's scoring of postoperative ischemia 24h, 72h, 7d, learn by statistics and handle, significance meaning (P＜0.05) is all arranged, explanation is intervened through the apoplexy oral liquid with the kidney invigorating effect and benefiting QI for activating blood circulation effect of the present invention, its function of nervous system's scoring is minimum, and the result shows that the present invention can reduce function of nervous system's scoring of acute lasting rats with cerebral ischemia, is better than matched group.
2. take out the brain water content that 6 rats are observed 24h, 72h behind the ischemias, 7d at random for every group, and relatively, learn by statistics and handle, significance meaning (P＜0.01) is all arranged, illustrate through the cerebral edema of apoplexy oral liquid intervention of the present invention the lightest.
3. immuning tissue's feature: bFGF positive cell sum and the positive cell gray scale of analyzing 24h, 72h behind the ischemia, 7d, each group compares, by statistical procedures, equal significance, positive cell sum and positive cell gray scale expressed after apoplexy oral liquid of the present invention intervention are the highest, illustrate that the present invention can improve the bFGF positive cell sum and the cell gray scale of acute lasting rats with cerebral ischemia, its bFGF is expressed strengthen, promote the reparation of ischemic tissue of brain.
Claims (3)
1. apoplexy oral liquid, it is characterized in that: prescription comprises following dosage component: Radix Rehmanniae Preparata 19-29 gram, Fructus Corni 10-14 gram, dried Rhizoma Dioscoreae 10-14 gram, Rhizoma Alismatis 7-11 gram, Cortex Moutan 7-11 gram, Poria 10-14 gram, Radix Astragali 90-140 gram, Rhizoma Chuanxiong 1-5 gram, concentrated decotion.
2. apoplexy oral liquid according to claim 1 is characterized in that: component also includes Semen Persicae 1-5 gram, Pheretima 1-5 gram.
3. apoplexy oral liquid according to claim 1 and 2, the application in the medicine of preparation treatment cerebral infarction acute phase of disease, convalescent period and sequela stage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100349592A CN100493558C (en) | 2006-04-12 | 2006-04-12 | Oral liquid for apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100349592A CN100493558C (en) | 2006-04-12 | 2006-04-12 | Oral liquid for apoplexy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872255A CN1872255A (en) | 2006-12-06 |
| CN100493558C true CN100493558C (en) | 2009-06-03 |
Family
ID=37482964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100349592A Active CN100493558C (en) | 2006-04-12 | 2006-04-12 | Oral liquid for apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100493558C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552628A (en) * | 2012-01-09 | 2012-07-11 | 李承平 | Pharmaceutical composition for nourishing yin and tonifying kidney |
| CN105434987A (en) * | 2015-12-29 | 2016-03-30 | 杜小卫 | Traditional Chinese medicine preparation for treating cerebral infarction |
-
2006
- 2006-04-12 CN CNB2006100349592A patent/CN100493558C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1872255A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463349B (en) | Traditional Chinese medicine composition for treating acute lumbar sprain | |
| CN1079253C (en) | Medicinal oil for dredging channels and collaterals of heart and brain and its preparing process | |
| CN105031088A (en) | Foot bathing powder for treating rheumatoid arthritis and preparation method thereof | |
| CN105213995A (en) | A kind of Chinese medicine composition for the treatment of verruca plana | |
| CN103933200B (en) | A kind of Chinese medicine composition for the treatment of apoplexy sequela | |
| CN100998656A (en) | Medicated wine for tonifying bone and removing obstruction in channels | |
| CN103316141B (en) | Traditional Chinese medicine composition for treating cervical spondylosis | |
| CN103007169A (en) | Traditional Chinese medicine composition for treating insomnia | |
| CN105031213A (en) | Traditional Chine medicine foot bathing powder for treating arthritis and preparation method thereof | |
| CN101181449A (en) | Medicine liqueur for curing osteoproliferation | |
| CN104758743A (en) | Traditional Chinese medicine foot fumigating powder for treating rheumatism as well as preparation method and using method thereof | |
| CN100493558C (en) | Oral liquid for apoplexy | |
| CN1296093C (en) | Cervical vertebrae drawing medicine bag | |
| CN104645078A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN101683471A (en) | Traditional Chinese medicine composition with function of brain tonic and vein relaxing | |
| CN102430030B (en) | Chinese medicinal composition for treating bone impediment | |
| CN102512543B (en) | Chinese medicinal composition for treating rheumatoid arthritis | |
| CN105477330A (en) | Traditional Chinese medicine composition for treating arrhythmia | |
| CN101401906A (en) | Anshen oral liquid for treating aypnia | |
| CN105079515A (en) | Traditional Chinese medicine composition for treating post-traumatic headache | |
| CN104740450A (en) | Traditional Chinese medicine foot bath powder for treating rheumatism and preparation and application method of traditional Chinese medicine foot bath powder | |
| CN103099889B (en) | Traditional Chinese medicine wine for treating lumbar spinal stenosis | |
| CN102349983A (en) | Traditional Chinese medicine composition for treating ischemic apoplexia | |
| CN103550437B (en) | A kind of Chinese medicine composition for the treatment of the hepatic and renal YIN deficiency | |
| CN102784212A (en) | Chinese medicine composition for treating arthralgia-synadrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |